UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>HER2-positive (HER2+) breast cancer accounts for 20–30% of all breast cancers. Although trastuzumab has significantly improved the survival of patients with HER2+ breast cancer, more than 70% of patients develop drug resistance within one year of treatment. Understanding the molecular mechanisms of trastuzumab resistance and identifying biomarkers that predict e...

Topics

Open a Topic to create a Post that cites this publication.

• Antibodies, Monoclonal, Humanized
• Cancer-related molecular mechanisms research
• Caveolin 1
• Principal Component Analysis
• Real-Time Polymerase Chain Reaction
• Receptor, ErbB-2
• Sequence Analysis, RNA
• Trastuzumab

Identifiers and source

Literature Corpus work

5a38d198-3cdf-5c59-b0b5-935b19f480f7

DOI

10.21203/rs.3.rs-3878357/v1